Search Results - "Robb, Merlin L."

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 by Sadoff, Jerald, Gray, Glenda, Vandebosch, An, Cárdenas, Vicky, Shukarev, Georgi, Grinsztejn, Beatriz, Goepfert, Paul A, Truyers, Carla, Fennema, Hein, Spiessens, Bart, Offergeld, Kim, Scheper, Gert, Taylor, Kimberly L, Robb, Merlin L, Treanor, John, Barouch, Dan H, Stoddard, Jeffrey, Ryser, Martin F, Marovich, Mary A, Neuzil, Kathleen M, Corey, Lawrence, Cauwenberghs, Nancy, Tanner, Tamzin, Hardt, Karin, Ruiz-Guiñazú, Javier, Le Gars, Mathieu, Schuitemaker, Hanneke, Van Hoof, Johan, Struyf, Frank, Douoguih, Macaya

“…Ad26.COV2.S vaccine is a replication-incompetent human adenovirus type 26 vector containing the gene sequence that produces SARS-CoV-2 spike protein in a…”
Get full text

Persistent, Albeit Reduced, Chronic Inflammation in Persons Starting Antiretroviral Therapy in Acute HIV Infection by Sereti, Irini, Krebs, Shelly J., Phanuphak, Nittaya, Fletcher, James L., Slike, Bonnie, Pinyakorn, Suteeraporn, O'Connell, Robert J., Rupert, Adam, Chomont, Nicolas, Valcour, Victor, Kim, Jerome H., Robb, Merlin L., Michael, Nelson L., Douek, Daniel C., Ananworanich, Jintanat, Utay, Netanya S.

“…Background. Serious non-AIDS events cause substantial disease and death despite human immunodeficiency virus (HIV) suppression with antiretroviral therapy…”
Get full text

Prospective Study of Acute HIV-1 Infection in Adults in East Africa and Thailand by Robb, Merlin L, Eller, Leigh A, Kibuuka, Hannah, Rono, Kathleen, Maganga, Lucas, Nitayaphan, Sorachai, Kroon, Eugene, Sawe, Fred K, Sinei, Samuel, Sriplienchan, Somchai, Jagodzinski, Linda L, Malia, Jennifer, Manak, Mark, de Souza, Mark S, Tovanabutra, Sodsai, Sanders-Buell, Eric, Rolland, Morgane, Dorsey-Spitz, Julie, Eller, Michael A, Milazzo, Mark, Li, Qun, Lewandowski, Andrew, Wu, Hao, Swann, Edith, O'Connell, Robert J, Peel, Sheila, Dawson, Peter, Kim, Jerome H, Michael, Nelson L

“…Acute human immunodeficiency virus type 1 (HIV-1) infection is a major contributor to transmission of HIV-1. An understanding of acute HIV-1 infection may be…”
Get full text

Initiation of ART during early acute HIV infection preserves mucosal Th17 function and reverses HIV-related immune activation by Schuetz, Alexandra, Deleage, Claire, Sereti, Irini, Rerknimitr, Rungsun, Phanuphak, Nittaya, Phuang-Ngern, Yuwadee, Estes, Jacob D, Sandler, Netanya G, Sukhumvittaya, Suchada, Marovich, Mary, Jongrakthaitae, Surat, Akapirat, Siriwat, Fletscher, James L K, Kroon, Eugene, Dewar, Robin, Trichavaroj, Rapee, Chomchey, Nitiya, Douek, Daniel C, O Connell, Robert J, Ngauy, Viseth, Robb, Merlin L, Phanuphak, Praphan, Michael, Nelson L, Excler, Jean-Louis, Kim, Jerome H, de Souza, Mark S, Ananworanich, Jintanat

“…Mucosal Th17 cells play an important role in maintaining gut epithelium integrity and thus prevent microbial translocation. Chronic HIV infection is…”
Get full text

Long-term sequelae after Ebola virus disease in Bundibugyo, Uganda: a retrospective cohort study by Clark, Danielle V, Dr, Kibuuka, Hannah, MD, Millard, Monica, MPH, Wakabi, Salim, MD, Lukwago, Luswa, MPH, Taylor, Alison, BS, Eller, Michael A, PhD, Eller, Leigh Anne, PhD, Michael, Nelson L, MD, Honko, Anna N, PhD, Olinger, Gene G, PhD, Schoepp, Randal J, PhD, Hepburn, Matthew J, MD, Hensley, Lisa E, PhD, Robb, Merlin L, MD

“…Summary Background The limited data available for long-term Ebola virus disease health outcomes suggest that sequelae persist for longer than 1 year after…”
Get full text

Circulating HIV-Specific Interleukin-21+CD4+ T Cells Represent Peripheral Tfh Cells with Antigen-Dependent Helper Functions by Schultz, Bruce T., Teigler, Jeffrey E., Pissani, Franco, Oster, Alexander F., Kranias, Gregory, Alter, Galit, Marovich, Mary, Eller, Michael A., Dittmer, Ulf, Robb, Merlin L., Kim, Jerome H., Michael, Nelson L., Bolton, Diane, Streeck, Hendrik

“…A central effort in HIV vaccine development is to generate protective broadly neutralizing antibodies, a process dependent on T follicular helper (Tfh) cells…”
Get full text

Nonneutralizing functional antibodies: a new "old" paradigm for HIV vaccines by Excler, Jean-Louis, Ake, Julie, Robb, Merlin L, Kim, Jerome H, Plotkin, Stanley A

“…Animal and human data from various viral infections and vaccine studies suggest that nonneutralizing antibodies (nNAb) without neutralizing activity in vitro…”
Get full text

Protective Efficacy of a Global HIV-1 Mosaic Vaccine against Heterologous SHIV Challenges in Rhesus Monkeys by Barouch, Dan H., Stephenson, Kathryn E., Borducchi, Erica N., Smith, Kaitlin, Stanley, Kelly, McNally, Anna G., Liu, Jinyan, Abbink, Peter, Maxfield, Lori F., Seaman, Michael S., Dugast, Anne-Sophie, Alter, Galit, Ferguson, Melissa, Li, Wenjun, Earl, Patricia L., Moss, Bernard, Giorgi, Elena E., Szinger, James J., Eller, Leigh Anne, Billings, Erik A., Rao, Mangala, Tovanabutra, Sodsai, Sanders-Buell, Eric, Weijtens, Mo, Pau, Maria G., Schuitemaker, Hanneke, Robb, Merlin L., Kim, Jerome H., Korber, Bette T., Michael, Nelson L.

“…The global diversity of HIV-1 represents a critical challenge facing HIV-1 vaccine development. HIV-1 mosaic antigens are bioinformatically optimized…”
Get full text

V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144 by Perez, Lautaro G, Martinez, David R, deCamp, Allan C, Pinter, Abraham, Berman, Phillip W, Francis, Donald, Sinangil, Faruk, Lee, Carter, Greene, Kelli, Gao, Hongmei, Nitayaphan, Sorachai, Rerks-Ngarm, Supachai, Kaewkungwal, Jaranit, Pitisuttithum, Punnee, Tartaglia, James, O'Connell, Robert J, Robb, Merlin L, Michael, Nelson L, Kim, Jerome H, Gilbert, Peter, Montefiori, David C

“…Non-neutralizing IgG to the V1V2 loop of HIV-1 gp120 correlates with a decreased risk of HIV-1 infection but the mechanism of protection remains unknown. This…”
Get full text

Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial by Gottardo, Raphael, Bailer, Robert T, Korber, Bette T, Gnanakaran, S, Phillips, Joshua, Shen, Xiaoying, Tomaras, Georgia D, Turk, Ellen, Imholte, Gregory, Eckler, Larry, Wenschuh, Holger, Zerweck, Johannes, Greene, Kelli, Gao, Hongmei, Berman, Phillip W, Francis, Donald, Sinangil, Faruk, Lee, Carter, Nitayaphan, Sorachai, Rerks-Ngarm, Supachai, Kaewkungwal, Jaranit, Pitisuttithum, Punnee, Tartaglia, James, Robb, Merlin L, Michael, Nelson L, Kim, Jerome H, Zolla-Pazner, Susan, Haynes, Barton F, Mascola, John R, Self, Steve, Gilbert, Peter, Montefiori, David C

“…Neutralizing and non-neutralizing antibodies to linear epitopes on HIV-1 envelope glycoproteins have potential to mediate antiviral effector functions that…”
Get full text

Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys by Barouch, Dan H., Liu, Jinyan, Li, Hualin, Maxfield, Lori F., Abbink, Peter, Lynch, Diana M., Iampietro, M. Justin, SanMiguel, Adam, Seaman, Michael S., Ferrari, Guido, Forthal, Donald N., Ourmanov, Ilnour, Hirsch, Vanessa M., Carville, Angela, Mansfield, Keith G., Stablein, Donald, Pau, Maria G., Schuitemaker, Hanneke, Sadoff, Jerald C., Billings, Erik A., Rao, Mangala, Robb, Merlin L., Kim, Jerome H., Marovich, Mary A., Goudsmit, Jaap, Michael, Nelson L.

“…Protective efficacy of novel vaccine candidates in rhesus monkeys opens new paths for the development of an HIV-1 vaccine. Vaccines protect against virulent…”
Get full text

HIV virologic failure and its predictors among HIV-infected adults on antiretroviral therapy in the African Cohort Study by Kiweewa, Francis, Esber, Allahna, Musingye, Ezra, Reed, Domonique, Crowell, Trevor A, Cham, Fatim, Semwogerere, Michael, Namagembe, Rosemary, Nambuya, Alice, Kafeero, Cate, Tindikahwa, Allan, Eller, Leigh Anne, Millard, Monica, Gelderblom, Huub C, Keshinro, Babajide, Adamu, Yakubu, Maswai, Jonah, Owuoth, John, Sing'oei, Valentine Chepkorir, Maganga, Lucas, Bahemana, Emmanuel, Khamadi, Samoel, Robb, Merlin L, Ake, Julie A, Polyak, Christina S, Kibuuka, Hannah

“…The 2016 WHO consolidated guidelines on the use of antiretroviral drugs defines HIV virologic failure for low and middle income countries (LMIC) as plasma…”
Get full text

HIV DNA Set Point is Rapidly Established in Acute HIV Infection and Dramatically Reduced by Early ART by Ananworanich, Jintanat, Chomont, Nicolas, Eller, Leigh Ann, Kroon, Eugene, Tovanabutra, Sodsai, Bose, Meera, Nau, Martin, Fletcher, James L.K., Tipsuk, Somporn, Vandergeeten, Claire, O'Connell, Robert J., Pinyakorn, Suteeraporn, Michael, Nelson, Phanuphak, Nittaya, Robb, Merlin L.

“…HIV DNA is a marker of HIV persistence that predicts HIV progression and remission, but its kinetics in early acute HIV infection (AHI) is poorly understood…”
Get full text

HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities by Pollara, Justin, Bonsignori, Mattia, Moody, M Anthony, Liu, Pinghuang, Alam, S Munir, Hwang, Kwan-Ki, Gurley, Thaddeus C, Kozink, Daniel M, Armand, Lawrence C, Marshall, Dawn J, Whitesides, John F, Kaewkungwal, Jaranit, Nitayaphan, Sorachai, Pitisuttithum, Punnee, Rerks-Ngarm, Supachai, Robb, Merlin L, O'Connell, Robert J, Kim, Jerome H, Michael, Nelson L, Montefiori, David C, Tomaras, Georgia D, Liao, Hua-Xin, Haynes, Barton F, Ferrari, Guido

“…The RV144 ALVAC/AIDSVax HIV-1 vaccine clinical trial showed an estimated vaccine efficacy of 31.2%. Viral genetic analysis identified a vaccine-induced site of…”
Get full text

TLR7 agonist, N6-LS and PGT121 delayed viral rebound in SHIV-infected macaques after antiretroviral therapy interruption by Hsu, Denise C, Schuetz, Alexandra, Imerbsin, Rawiwan, Silsorn, Decha, Pegu, Amarendra, Inthawong, Dutsadee, Sopanaporn, Jumpol, Visudhiphan, Pornsuk, Chuenarom, Weerawan, Keawboon, Boot, Shi, Wei, Robb, Merlin L, Mascola, John R, Geleziunas, Romas, Koup, Richard A, Barouch, Dan H, Michael, Nelson L, Vasan, Sandhya

“…Toll-like receptor 7 (TLR7) agonist and PGT121 (broadly neutralizing antibody, bnAb) administration previously delayed viral rebound and induced SHIV…”
Get full text

Durability of protection and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine over 6 months by Sobieszczyk, Magdalena E, Maaske, Jill, Falsey, Ann R, Sproule, Stephanie, Robb, Merlin L, Frenck, Jr, Robert W, Tieu, Hong-Van, Mayer, Kenneth H, Corey, Lawrence, Neuzil, Kathleen M, Tong, Tina, Brewinski Isaacs, Margaret, Janes, Holly, Bansal, Himanshu, Edwards, Lindsay M, Green, Justin A, Kelly, Elizabeth J, Shoemaker, Kathryn, Takas, Therese, White, Tom, Bhuyan, Prakash, Villafana, Tonya, Hirsch, And Ian

“…BackgroundWe report updated safety, efficacy, and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) from an ongoing phase 3 trial.MethodsAdults at increased risk of…”
Get full text

The breadth of HIV-1 neutralizing antibodies depends on the conservation of key sites in their epitopes by Bai, Hongjun, Li, Yifan, Michael, Nelson L, Robb, Merlin L, Rolland, Morgane

“…Developing HIV-1 vaccines that trigger broadly neutralizing antibodies (bnAbs) is a priority as bnAbs are considered key to elicitation of a protective immune…”
Get full text

Prevention of SIVmac251 reservoir seeding in rhesus monkeys by early antiretroviral therapy by Whitney, James B., Lim, So-Yon, Osuna, Christa E., Kublin, Jessica L., Chen, Elsa, Yoon, Gyeol, Liu, Po-Ting, Abbink, Peter, Borducci, Erica N., Hill, Alison, Lewis, Mark G., Geleziunas, Romas, Robb, Merlin L., Michael, Nelson L., Barouch, Dan H.

“…The precise time when the viral reservoir is seeded during acute HIV-1 infection remains unclear. We previously demonstrated that the viral reservoir was…”
Get full text

International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations by Barouch, Dan H, Kik, Sandra V, Weverling, Gerrit J, Dilan, Rebecca, King, Sharon L, Maxfield, Lori F, Clark, Sarah, Ng’ang’a, David, Brandariz, Kara L, Abbink, Peter, Sinangil, Faruk, de Bruyn, Guy, Gray, Glenda E, Roux, Surita, Bekker, Linda-Gail, Dilraj, Athmanundh, Kibuuka, Hannah, Robb, Merlin L, Michael, Nelson L, Anzala, Omu, Amornkul, Pauli N, Gilmour, Jill, Hural, John, Buchbinder, Susan P, Seaman, Michael S, Dolin, Raphael, Baden, Lindsey R, Carville, Angela, Mansfield, Keith G, Pau, Maria G, Goudsmit, Jaap

“…Abstract Recombinant adenovirus serotype 5 (rAd5) vaccine vectors for HIV-1 and other pathogens have been shown to be limited by high titers of Ad5…”
Get full text

Adjuvanted HIV-1 vaccine promotes antibody-dependent phagocytic responses and protects against heterologous SHIV challenge by Om, Kier, Paquin-Proulx, Dominic, Montero, Maria, Peachman, Kristina, Shen, Xiaoying, Wieczorek, Lindsay, Beck, Zoltan, Weiner, Joshua A, Kim, Dohoon, Li, Yifan, Mdluli, Thembi, Shubin, Zhanna, Bryant, Christopher, Sharma, Vishakha, Tokarev, Andrey, Dawson, Peter, White, Yohann, Appelbe, Oliver, Klatt, Nichole R, Tovanabutra, Sodsai, Estes, Jacob D, Matyas, Gary R, Ferrari, Guido, Alving, Carl R, Tomaras, Georgia D, Ackerman, Margaret E, Michael, Nelson L, Robb, Merlin L, Polonis, Victoria, Rolland, Morgane, Eller, Michael A, Rao, Mangala, Bolton, Diane L

“…To augment HIV-1 pox-protein vaccine immunogenicity using a next generation adjuvant, a prime-boost strategy of recombinant modified vaccinia virus Ankara and…”
Get full text